China Pharma Holdings, Inc. (CPHI) stock
CPHINYSEPharmaceutical PreparationsFiscal year ends December 31
$0.54−0.01 (-1.43%)
Close on Nov 11, 2026Market cap $23.37MP/E –Yield –
China Pharma r&d expenses
Research and development expenses are spending on new products and technology.
China Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $333.26K, up 140.3% year over year. For fiscal 2025 it was $280.90K, down 1.1% from the year before. Over ten years it grew -11.6% a year on average. The highest annual figure on record is $2.80M in fiscal 2014.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $280.90K | -1.1% |
| FY2024 | Dec 31, 2024 | $283.94K | +18.3% |
| FY2023 | Dec 31, 2023 | $240.08K | +29.2% |
| FY2022 | Dec 31, 2022 | $185.86K | -41.7% |
| FY2021 | Dec 31, 2021 | $318.96K | -15.6% |
| FY2020 | Dec 31, 2020 | $377.96K | +64.6% |
| FY2019 | Dec 31, 2019 | $229.64K | +33.2% |
| FY2018 | Dec 31, 2018 | $172.38K | +90.5% |
| FY2017 | Dec 31, 2017 | $90.47K | -75.3% |
| FY2016 | Dec 31, 2016 | $365.97K | -62.0% |
| FY2015 | Dec 31, 2015 | $961.90K | -65.6% |
| FY2014 | Dec 31, 2014 | $2.80M | +66.3% |
| FY2013 | Dec 31, 2013 | $1.68M | +283.7% |
| FY2012 | Dec 31, 2012 | $438.66K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.14K | -8.7% |
| Q1 FY2026 | Mar 31, 2026 | $83.76K | +183.1% |
| Q4 FY2025 | Dec 31, 2025 | $190.04K | +34642.4% |
| Q3 FY2025 | Sep 30, 2025 | $40.32K | -54.0% |
| Q2 FY2025 | Jun 30, 2025 | $20.95K | -87.3% |
| Q1 FY2025 | Mar 31, 2025 | $29.59K | -5.9% |
| Q4 FY2024 | Dec 31, 2024 | $547 | -99.6% |
| Q3 FY2024 | Sep 30, 2024 | $87.61K | +91.4% |
| Q2 FY2024 | Jun 30, 2024 | $164.33K | +592.0% |
| Q1 FY2024 | Mar 31, 2024 | $31.45K | +36.7% |
| Q4 FY2023 | Dec 31, 2023 | $147.55K | +427.0% |
| Q3 FY2023 | Sep 30, 2023 | $45.77K | -48.4% |
| Q2 FY2023 | Jun 30, 2023 | $23.75K | +57.7% |
| Q1 FY2023 | Mar 31, 2023 | $23.01K | -57.4% |
| Q4 FY2022 | Dec 31, 2022 | $28.00K | -48.2% |
| Q3 FY2022 | Sep 30, 2022 | $88.75K | +315.2% |
| Q2 FY2022 | Jun 30, 2022 | $15.06K | -71.8% |
| Q1 FY2022 | Mar 31, 2022 | $54.05K | -71.6% |
| Q4 FY2021 | Dec 31, 2021 | $54.05K | -79.3% |
| Q3 FY2021 | Sep 30, 2021 | $21.37K | -43.2% |
| Q2 FY2021 | Jun 30, 2021 | $53.46K | +77.9% |
| Q1 FY2021 | Mar 31, 2021 | $190.09K | +289.4% |
| Q4 FY2020 | Dec 31, 2020 | $261.47K | +384.3% |
| Q3 FY2020 | Sep 30, 2020 | $37.63K | -5.3% |
| Q2 FY2020 | Jun 30, 2020 | $30.04K | -54.5% |
| Q1 FY2020 | Mar 31, 2020 | $48.82K | -30.2% |
| Q4 FY2019 | Dec 31, 2019 | $54.00K | -16.2% |
| Q3 FY2019 | Sep 30, 2019 | $39.72K | -36.0% |
| Q2 FY2019 | Jun 30, 2019 | $66.01K | +178.8% |
| Q1 FY2019 | Mar 31, 2019 | $69.92K | +214.8% |
| Q4 FY2018 | Dec 31, 2018 | $64.44K | +317.9% |
| Q3 FY2018 | Sep 30, 2018 | $62.06K | +125.3% |
| Q2 FY2018 | Jun 30, 2018 | $23.67K | +10.4% |
| Q1 FY2018 | Mar 31, 2018 | $22.21K | -14.8% |
| Q4 FY2017 | Dec 31, 2017 | $15.42K | -79.9% |
| Q3 FY2017 | Sep 30, 2017 | $27.54K | -72.2% |
| Q2 FY2017 | Jun 30, 2017 | $21.45K | – |
| Q1 FY2017 | Mar 31, 2017 | $26.06K | – |
| Q4 FY2016 | Dec 31, 2016 | $76.78K | – |
| Q3 FY2016 | Sep 30, 2016 | $99.10K | – |
See a number that looks wrong?